血小板活化因子(platelet-activating factor,PAF)是哮喘发病的介质之一。现已发现的PAF拮抗剂有多种,大部分均有抗哮喘作用,其中一些作用强、口服易吸收、副作用小的化合物有可能在哮喘的治疗中发挥作用。然而,哮喘是由多种介质所引起,PAF拮抗剂只有在与其它介质拮抗剂联合应用时,疗效才会更理想。 Platelet-activating factor (PAF) is one of the pathogenesis of asthma. PAF antagonists have been found in a variety of, most have anti-asthma effects, some of which are strong, oral absorption of compounds with less side effects may have a role in the treatment of asthma. However, asthma is caused by a variety of mediators and PAF antagonists are more effective only when used in combination with other antagonists.